Kiromic BioPharma Inc. (KRBP)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | n/a |
Market Cap | 2.53M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -6.22 |
PE Ratio (ttm) | -0.27 |
Forward PE | n/a |
Analyst | n/a |
Ask | n/a |
Volume | 100 |
Avg. Volume (20D) | 1,713 |
Open | 1.65 |
Previous Close | 1.66 |
Day's Range | 1.65 - 1.65 |
52-Week Range | 0.75 - 3.78 |
Beta | undefined |
About KRBP
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candi...
News

2 months ago · businesswire.com
Kiromic BioPharma Announces Settlement of Previously Disclosed SEC InvestigationHOUSTON--(BUSINESS WIRE)---- $KRBP--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) today announced that it has entered into a settlement agreement with the U.S. Securities and Exch...